• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Collins James J.

    6/27/25 7:55:15 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SNTI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Collins James J.

    (Last) (First) (Middle)
    C/O SENTI BIOSCIENCES, INC.
    2 CORPORATE DRIVE FIRST FLOOR

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Senti Biosciences, Inc. [ SNTI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/25/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $2.05 06/25/2025 A 21,950 (1) 06/24/2035 Common Stock 21,950 $0 21,950 D
    Explanation of Responses:
    1. 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.
    /s/ Timothy Lu, attorney-in-fact 06/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SNTI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNTI

    DatePrice TargetRatingAnalyst
    6/6/2025$5.00Buy
    Laidlaw
    10/7/2022$7.50Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SNTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Laidlaw initiated coverage on Senti Bio with a new price target

      Laidlaw initiated coverage of Senti Bio with a rating of Buy and set a new price target of $5.00

      6/6/25 8:36:59 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley initiated coverage on Senti Bio with a new price target

      Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50

      10/7/22 7:14:34 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    SEC Filings

    See more
    • Senti Biosciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Senti Biosciences, Inc. (0001854270) (Filer)

      7/18/25 8:56:49 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Senti Biosciences, Inc. (0001854270) (Filer)

      6/30/25 4:02:07 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Senti Biosciences, Inc. (0001854270) (Filer)

      6/18/25 7:05:30 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Baum Bryan Daniel

      4 - Senti Biosciences, Inc. (0001854270) (Issuer)

      7/21/25 5:56:55 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Baum Bryan Daniel

      3 - Senti Biosciences, Inc. (0001854270) (Issuer)

      7/21/25 5:55:39 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Collins James J.

      4 - Senti Biosciences, Inc. (0001854270) (Issuer)

      6/27/25 7:55:15 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

      SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the BioScience Forum being held July 23, 2025 in San Carlos, CA. Details of the presentation are as follows: Title: Using Logic Gated CARs to Drive Cancer TreatmentSpeaker: Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti BioDate and Time: Wednesday, July 23rd at 6:00 PM PT The BioScience Forum is a non-profit educational forum

      7/21/25 8:55:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

      SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Bryan Baum to its Board of Directors. Mr. Baum is a serial entrepreneur and investor and is the Co-Founder and Managing Partner of K5 Global. His portfolio includes category-defining companies such as SpaceX, xAI, Anduril, Canva, Databricks, Grafana, OpenAI, and others. He has also founded and successfully exited multiple ventures. Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder

      7/18/25 8:55:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio Participates in Nasdaq Amplify Spotlight Series

      Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer recently participated in Nasdaq's Amplify Spotlight Series. As part of the segment, Dr. Lu provided a corporate overview and highlighted how Senti is leveraging its proprietary Gene Circuit platform to develop next-generation cell and gene therapies for the treatment of challenging liquid and solid tumor indications. T

      6/30/25 9:15:41 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Leadership Updates

    Live Leadership Updates

    See more
    • Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

      Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from "bench to bedside" and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisor

      4/10/25 8:45:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Financials

    Live finance-specific insights

    See more
    • Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

      SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the BioScience Forum being held July 23, 2025 in San Carlos, CA. Details of the presentation are as follows: Title: Using Logic Gated CARs to Drive Cancer TreatmentSpeaker: Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti BioDate and Time: Wednesday, July 23rd at 6:00 PM PT The BioScience Forum is a non-profit educational forum

      7/21/25 8:55:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

      SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Bryan Baum to its Board of Directors. Mr. Baum is a serial entrepreneur and investor and is the Co-Founder and Managing Partner of K5 Global. His portfolio includes category-defining companies such as SpaceX, xAI, Anduril, Canva, Databricks, Grafana, OpenAI, and others. He has also founded and successfully exited multiple ventures. Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder

      7/18/25 8:55:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio Participates in Nasdaq Amplify Spotlight Series

      Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer recently participated in Nasdaq's Amplify Spotlight Series. As part of the segment, Dr. Lu provided a corporate overview and highlighted how Senti is leveraging its proprietary Gene Circuit platform to develop next-generation cell and gene therapies for the treatment of challenging liquid and solid tumor indications. T

      6/30/25 9:15:41 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

      SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

      12/4/24 7:08:03 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Senti Biosciences Inc.

      SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)

      2/14/23 12:38:17 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Senti Biosciences Inc. (Amendment)

      SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

      2/14/23 11:52:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care